Still, our findings indicated that ZIC5 upregulation was associated with metastatic status in PCa patients and that ZIC5 might also be a prognostic marker for patients suffering from metastatic PCa, as well as a relevant therapeutic target. This evidence concerns the gene ZIC5 and posterior cortical atrophy.